{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is postulated to be a key molecule in the etiology of both familial and sporadic PD. The molecular mechanism whereby mutant LRRK2 causes loss of dopaminergic neurons has not yet been confirmed.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro pull-down and kinase assays using recombinant proteins proved that Akt1 is the direct downstream substrate of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models or reflects the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Recombinant human Akt1 (His-tagged protein) was subjected to in vitro [c-32 P]ATP phosphorylation assay with recombinant human LRRK2 (GST-tagged wild-type protein consisting of all the functional domains in the stretch incorporating amino acid residues 970-2527).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay for this variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The three LRRK2 mutants exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "No",
          "reasoning": "Statistical analyses in the paper are not sufficient to estimate or calculate OddsPath for the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "At least 11 variant controls were used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R1441C variant in LRRK2 exhibits reduced interaction with, and phosphorylation of, Akt1, suggesting a possible mechanism for neurodegeneration in Parkinson's disease. The functional evidence supports a moderate strength pathogenic rating due to the use of variant controls and the significant reduction in kinase activity."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is postulated to be a key molecule in the etiology of both familial and sporadic PD. The molecular mechanism whereby mutant LRRK2 causes loss of dopaminergic neurons has not yet been confirmed.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro pull-down and kinase assays using recombinant proteins proved that Akt1 is the direct downstream substrate of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models or reflects the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Recombinant human Akt1 (His-tagged protein) was subjected to in vitro [c-32 P]ATP phosphorylation assay with recombinant human LRRK2 (GST-tagged wild-type protein consisting of all the functional domains in the stretch incorporating amino acid residues 970-2527).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay for this variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The three LRRK2 mutants exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "No",
          "reasoning": "Statistical analyses in the paper are not sufficient to estimate or calculate OddsPath for the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "At least 11 variant controls were used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The G2019S variant in LRRK2 exhibits reduced interaction with, and phosphorylation of, Akt1, suggesting a possible mechanism for neurodegeneration in Parkinson's disease. The functional evidence supports a moderate strength pathogenic rating due to the use of variant controls and the significant reduction in kinase activity."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 is postulated to be a key molecule in the etiology of both familial and sporadic PD. The molecular mechanism whereby mutant LRRK2 causes loss of dopaminergic neurons has not yet been confirmed.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay being described for this variant."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro pull-down and kinase assays using recombinant proteins proved that Akt1 is the direct downstream substrate of LRRK2.",
          "judgment": "Yes",
          "reasoning": "The general class of assay used for this variant effectively models or reflects the disease pathogenesis/mechanism defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Recombinant human Akt1 (His-tagged protein) was subjected to in vitro [c-32 P]ATP phosphorylation assay with recombinant human LRRK2 (GST-tagged wild-type protein consisting of all the functional domains in the stretch incorporating amino acid residues 970-2527).",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were included for this assay.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "Variant controls were used in the assay for this variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The three LRRK2 mutants exhibited significantly weaker kinase activity of Akt1 (Ser473)-phosphorylation than the wild-type LRRK2.",
          "judgment": "No",
          "reasoning": "Statistical analyses in the paper are not sufficient to estimate or calculate OddsPath for the functional data for this variant.",
          "next_step_or_outcome": "Proceed to Sub-step 4b"
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The recombinant Akt1 was phosphorylated by the recombinant LRRK2 with the three known mutations, i.e., R1441C in the ROC domain, G2019S in the kinase domain, and I2020T in the kinase domain.",
          "judgment": "Yes",
          "reasoning": "At least 11 variant controls were used across the entire study.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The I2020T variant in LRRK2 exhibits reduced interaction with, and phosphorylation of, Akt1, suggesting a possible mechanism for neurodegeneration in Parkinson's disease. The functional evidence supports a moderate strength pathogenic rating due to the use of variant controls and the significant reduction in kinase activity."
    }
  ]
}